Therapeutic area intelligence for Mucopolysaccharidosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

JCR Pharmaceuticals →

Assets

Phase →

Recent signals(1)

ClinicalJuly 8, 2026

Phase I/II Trial of JR-446 for MPS IIIB Initiated by JCR Pharmaceuticals

A Phase I/II trial of JR-446 is underway to evaluate its safety and early clinical effects in young patients with MPS IIIB.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Genetic Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.